Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > July 5, 2022
Daily News
July 5, 2022
- MHLW Preparing Inspection Manual after GMP Issues, Draft Due Out by March-End
July 5, 2022
- Shionogi Starts Document Submission for COVID Pill in China
July 5, 2022
- BMS Japan Launches New Head Office as It Looks to Spur Ideas through Casual Chats
July 5, 2022
- JPMA Committed to Building Drug Discovery Ecosystem: President
July 5, 2022
- High Court Verdict for Bayer Employee Damage Suit Set for Sept. 7, Settlement Eyed Too
July 5, 2022
- Aculys, KNOCK ON THE DOOR Form Comprehensive Epilepsy Alliance
July 5, 2022
- Promotions via In-Hospital Seminars in HP Market Rise 28.4% YOY in May: Intage
July 5, 2022
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…